CONTACT trial results presented at UEGW 2016 meeting

Mauna Kea Technologies' results of its CONTACT clinical trial have been presented at the United European Gastroenterology Week (UEGW) 2016 meeting.
The CONTACT trial, which turned in positive results, used the Cellvizio confocal laser endomicroscopy to characterize pancreatic cysts.
“The characterization of pancreatic cysts remains a well-known medical challenge around the world. The very positive results presented today confirm the value of our technology in the field of pancreatic cancer prevention and will help the growing number of sites utilizing Cellvizio make better decisions for their patients who present with pancreatic lesions,” Mauna Kea Technologies Founder and CEO Sacha Loiseau said. “These very positive results, which come on the heels of the American Society of General Surgeons’ endorsement of Cellvizio for Barrett’s Esophagus and Gastroesophageal Reflux Disease, further highlight the value and utility of Cellvizio.”
The results of the CONTACT trial confirmed and improved upon the prior performance of nCLE in diagnosing of pancreatic cystic lesions. The results were presented by Bertrand Napoleon, who works at the Hospital Jean Mermoz in Lyon, France, in a presentation called “Needle-based confocal endomicroscopy for the diagnosis of solitary pancreatic cysts. A prospective multi-center study.”